Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-05-20Clinical Trial Update: A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer [Phase 2]
Phase 2 study of single-agent Carlumab in metastatic castration-resistant prostate cancer completed with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-05-20Clinical Trial Update: An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Intetumumab (CNTO 95) in metastatic castration-resistant prostate cancer has completed a…
-
CLINICAL_TRIALS trial_result · 2013-04-17Clinical Trial Update: Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 3]
A Phase 3 trial evaluated adding bevacizumab to docetaxel and prednisone in men with hormone-refractory prostate cancer; results were posted…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 drug-drug interaction study evaluating abiraterone acetate plus prednisone with dextromethorphan and theophylline in metastatic ca…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 study evaluating QT/QTc safety and multi-dose pharmacokinetics of abiraterone acetate plus prednisone in patients with metastatic ca…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-03-12Clinical Trial Update: Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC [Phase 1]
Phase I trial assessing ZD4054 (Zibotentan) in combination with docetaxel for metastatic castration-resistant prostate cancer; the study has…
-
CLINICAL_TRIALS trial_result · 2013-03-08Clinical Trial Update: Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy [Phase 3]
Phase 3 trial of sunitinib plus prednisone in metastatic castration-resistant prostate cancer after docetaxel failure; the study was termina…
-
CLINICAL_TRIALS trial_result · 2013-02-07Clinical Trial Update: RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer [Phase 2]
Phase 2 trial of RAD001 (everolimus) in metastatic, hormone-refractory prostate cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 2]
Phase 2 trial of BMS-275291 in hormone-resistant prostate cancer has completed. The study enrolled men with advanced disease, including thos…
-
CLINICAL_TRIALS trial_result · 2012-12-11Clinical Trial Update: A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating the clinical activity of tanespimycin (IPI-504) in hormone-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2012-10-30Clinical Trial Update: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy [Phase 3]
Phase 3 trial update for MDV3100 (enzalutamide) in castration-resistant prostate cancer previously treated with docetaxel; results posted af…
-
CLINICAL_TRIALS trial_result · 2012-10-26Clinical Trial Update: Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 [Phase 2]
Phase 2 trial evaluating the combination of docetaxel and imatinib mesylate in metastatic castration-resistant prostate cancer that progress…
-
CLINICAL_TRIALS trial_result · 2012-10-12Clinical Trial Update: Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases [Phase 2]
This Phase 2 trial update evaluates docetaxel with or without imatinib mesylate in patients with androgen-independent (castration-resistant)…
-
CLINICAL_TRIALS trial_result · 2012-10-01Clinical Trial Update: Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer [Phase 2]
A Phase II clinical trial evaluating Abraxane (paclitaxel protein-bound particles) as front-line therapy for metastatic castration-resistant…
-
CLINICAL_TRIALS trial_result · 2012-09-28Clinical Trial Update: A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer [Phase 2]
Phase II trial update reporting results for sorafenib in metastatic, androgen-independent prostate cancer (CRPC).
-
CLINICAL_TRIALS trial_result · 2012-09-24Clinical Trial Update: Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases [Phase 3]
Phase 3 trial update comparing strontium-89 with external-beam radiation therapy in men with metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS trial_result · 2012-08-29Clinical Trial Update: Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC [Phase 2]
Phase 2 trial evaluating OGX-011 in combination with second-line chemotherapy in hormone-refractory prostate cancer has completed and result…
-
CLINICAL_TRIALS trial_result · 2012-08-07Clinical Trial Update: Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen [Phase 3]
A Phase 3 trial evaluating satraplatin in hormone-refractory (castration-resistant) prostate cancer patients who had previously received one…
-
CLINICAL_TRIALS trial_result · 2012-07-18Clinical Trial Update: Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer [Phase 2]
This update reports the efficacy and safety results from a Phase 2 trial of Zactima (vandetanib) in patients with castration-refractory meta…
-
CLINICAL_TRIALS trial_result · 2012-05-31Clinical Trial Update: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer [Phase 3]
Phase III trial evaluating Zibotentan (ZD4054) in combination with docetaxel for metastatic castration-resistant prostate cancer has complet…
-
CLINICAL_TRIALS trial_result · 2012-05-11Clinical Trial Update: PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC [Phase 2]
A Phase 2 trial of docetaxel with prednisone and sargramostim for hormone-refractory (castration-resistant) prostate cancer has been termina…
-
CLINICAL_TRIALS trial_result · 2012-04-27Clinical Trial Update: Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy [Phase 1]
Phase 1 safety study of a Cytotoxic Lymphocytes (CTL)–based therapy for castration-resistant prostate cancer has completed.
-
CLINICAL_TRIALS trial_result · 2012-03-30Clinical Trial Update: RNActive®-Derived Therapeutic Vaccine [Phase 1, Phase 2]
A phase 1/2 clinical trial of an RNActive-derived therapeutic vaccine for castration-resistant prostate cancer was terminated, with results …
-
CLINICAL_TRIALS trial_result · 2012-03-15Clinical Trial Update: Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate [Phase 2]
Phase 2 trial evaluating docetaxel, estramustine, and thalidomide in metastatic castration-resistant prostate cancer has completed enrollmen…
-
CLINICAL_TRIALS trial_result · 2012-03-12Clinical Trial Update: A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer [Phase 2]
A Phase 2 study evaluating the combination of Mycobacterium w and docetaxel in metastatic castration-resistant prostate cancer has been term…